Keio University · 화학
마시노 다다히코 교수의 연구실은 나노소재 기반의 약물 개발과 암 치료 저항성 극복을 핵심 연구 분야로 삼고 있습니다. 특히 수용성 풀러렌 유도체를 활용한 암세포(apoptosis 유도) 및 항암제 내성 메커니즘(예: Nrf2 경로 조절)에 대한 기초 및 응용 연구를 진행하고 있습니다. 이는 암 치료의 효능을 높이고, 의료비 절감에 기여할 수 있는 새로운 전략을 모색하는 데 초점이 맞춰져 있습니다.
표시된 성과는 수집된 데이터 기준으로 산출되며, 일부 차이가 있을 수 있습니다.
The biological activities of C(60)-bis(N,N-dimethylpyrrolidinium iodide), a water-soluble cationic fullerene derivative, on human promyeloleukaemia (HL-60) cells were investigated. The pyrrolidinium fullerene derivative showed cytotoxicity in HL-60 cells. The characteristics of apoptosis, such as DNA fragmentation and condensation of chromatin in HL-60 cells, were observed by exposure to the pyrrolidinium fullerene derivative. Caspase-3 and -8 were activated and cytochrome c was also released fr
Resistance to anticancer agents has been an obstacle to developing therapeutics and reducing medical costs. Whereas sorafenib is used for the treatment of human hepatocellular carcinoma (HCC), resistance limits its efficacy. p62, a multifunctional protein, is overexpressed in several HCC cell lines, such as Huh-1 cells. Phosphorylated p62 (<i>p</i>-p62) inhibits the protein-protein interaction (PPI) between Keap1 and Nrf2, resulting in the Nrf2 overactivation that causes drug resistance. We have
